Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1211444.RAZ7tUxG36IROHiCqmt3_UnrcLQcEyHhhs_b-Gmf5pvMk130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1211444.RAZ7tUxG36IROHiCqmt3_UnrcLQcEyHhhs_b-Gmf5pvMk130_assertion type Assertion NP1211444.RAZ7tUxG36IROHiCqmt3_UnrcLQcEyHhhs_b-Gmf5pvMk130_head.
- NP1211444.RAZ7tUxG36IROHiCqmt3_UnrcLQcEyHhhs_b-Gmf5pvMk130_assertion description "[To date, the major therapeutic strategy to block the unwanted actions of ET in disease, principally in pulmonary arterial hypertension, has been to use antagonists that are selective for the ETA receptor (ambrisentan) or that block both receptor subtypes (bosentan).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1211444.RAZ7tUxG36IROHiCqmt3_UnrcLQcEyHhhs_b-Gmf5pvMk130_provenance.
- NP1211444.RAZ7tUxG36IROHiCqmt3_UnrcLQcEyHhhs_b-Gmf5pvMk130_assertion evidence source_evidence_literature NP1211444.RAZ7tUxG36IROHiCqmt3_UnrcLQcEyHhhs_b-Gmf5pvMk130_provenance.
- NP1211444.RAZ7tUxG36IROHiCqmt3_UnrcLQcEyHhhs_b-Gmf5pvMk130_assertion SIO_000772 25131455 NP1211444.RAZ7tUxG36IROHiCqmt3_UnrcLQcEyHhhs_b-Gmf5pvMk130_provenance.
- NP1211444.RAZ7tUxG36IROHiCqmt3_UnrcLQcEyHhhs_b-Gmf5pvMk130_assertion wasDerivedFrom befree-2016 NP1211444.RAZ7tUxG36IROHiCqmt3_UnrcLQcEyHhhs_b-Gmf5pvMk130_provenance.
- NP1211444.RAZ7tUxG36IROHiCqmt3_UnrcLQcEyHhhs_b-Gmf5pvMk130_assertion wasGeneratedBy ECO_0000203 NP1211444.RAZ7tUxG36IROHiCqmt3_UnrcLQcEyHhhs_b-Gmf5pvMk130_provenance.